P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN

P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN

Bibliographic Details
Main Authors:	B. yang, L. fu, H. li, H. chen, J. ma
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846128.40398.5b

Similar Items

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
by: Yufei Zhao, et al.
Published: (2023-01-01)

Role of eltrombopag in severe aplastic anemia treatment in children
by: Min-Yu Su, et al.
Published: (2021-11-01)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
by: Ruixin Li, et al.
Published: (2022-05-01)

NATIONAL EXPERIENCE WITH IMMUNOSUPPRESSIVE THERAPY AND ELTROMBOPAG IN CHILDREN WITH APLASTIC ANEMIA- REAL WORLD DATA
by: Katarzyna Pawelec, et al.
Published: (2023-12-01)

Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis
by: Yan Zhang, et al.
Published: (2024-04-01)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
by: Ashvind Prabahran, et al.
Published: (2023-08-01)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
by: Beatrice Drexler, et al.
Published: (2021-03-01)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
by: Ziqi Wan, et al.
Published: (2023-05-01)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
by: Hong Chang, et al.
Published: (2023-11-01)

P820: PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
by: R. Li, et al.
Published: (2022-06-01)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
by: Abdul Muqtadir Abbasi, et al.
Published: (2022-01-01)

Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
by: Limin Liu, et al.
Published: (2022-08-01)

Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia
by: Liangliang Wu, et al.
Published: (2024-03-01)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
by: Akiko Konishi, et al.
Published: (2019-01-01)

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
by: Maria Maddalena Marrapodi, et al.
Published: (2023-04-01)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
by: Ayşe Işık, et al.
Published: (2013-09-01)

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
by: Tremblay G, et al.
Published: (2019-11-01)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
by: Zhuxin Zhang, et al.
Published: (2023-09-01)

Immunosuppressive therapy in patients with aplastic anemia: a single-center retrospective study.
by: Hasan Jalaeikhoo, et al.
Published: (2015-01-01)

HEMATOLOGIC RECOVERY INDUCED BY ELTROMBOPAG IN PATIENT WITH APLASTIC ANEMIA AFTER TEMOZOLOMIDE
by: ACP Silva, et al.
Published: (2023-10-01)

Aplastic anemia: immunosuppressive therapy in 2010
by: Antonio M. Risitano, et al.
Published: (2011-06-01)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
by: Zhuxin Zhang, et al.
Published: (2023-08-01)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
by: H. Chang, et al.
Published: (2022-06-01)

P804: EX VIVO TREATMENT WITH ELTROMBOPAG RESCUES HEMATOPOIETIC STEM CELLS FROM ANTI-THYMOCYTE GLOBULIN-RELATED DAMAGE DURING IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA
by: M. Vieri, et al.
Published: (2022-06-01)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
by: Nesrine Ben Sayed, et al.
Published: (2023-08-01)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
by: Yihong Guan, et al.
Published: (2022-02-01)

Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
by: Wei Zuo, et al.
Published: (2020-11-01)

Comparison of intensive immunosuppressive therapy with haploidentical transplantation for young severe aplastic anemia
by: CHEN Miao, WU Ya-mei, ZHOU Dao-bin, DUAN Ming-hui, ZHUANG Jun-ling, HAN Bing, WU Xiao-xiong
Published: (2020-06-01)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
by: C. Ranjit Kumar, et al.
Published: (2022-06-01)

Immunosuppressive Treatment in Children with Acquired Aplastic Anemia
by: Yıldız Yıldırmak, et al.
Published: (2012-05-01)

Treatment response and its predictors of immunosuppressive therapy in patients with severe or very severe aplastic anemia
by: Thanakrit Somprasertkul, et al.
Published: (2024-06-01)

ELTROMBOPAG AS FIRST-LINE TREATMENT IN SEVERE APLASTIC ANEMIA: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
by: MA Salvino, et al.
Published: (2021-10-01)

Predictive value of thyroid function in severe aplastic anemia patients treated with immunosuppressive therapy
by: Yilin Liu, et al.
Published: (2024-04-01)

Predictive value of T cell receptor repertoire profiling for immunosuppressive therapy in severe aplastic anemia
by: Cunte Chen, et al.
Published: (2024-01-01)

P766: ELTROMBOPAG EFFECTIVELY ALLEVIATES APLASTIC ANEMIA THROUGH REDUCING AKT PROTEIN STABILITY AND MODULATING T LYMPHOCYTE SUBSETS
by: Zenghua Lin, et al.
Published: (2023-08-01)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
by: R. Li, et al.
Published: (2022-06-01)

Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review
by: Yuan Yang, et al.
Published: (2021-04-01)

Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia
by: Darren Kelly, et al.
Published: (2020-03-01)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
by: Margherita Vieri, et al.
Published: (2023-06-01)

Erratum on ‘‘Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective”
by: M.A. Salvino, et al.
Published: (2022-04-01)